Gladstone Institutional Advisory LLC Cuts Holdings in DexCom, Inc. (NASDAQ:DXCM)

Gladstone Institutional Advisory LLC lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 63.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,272 shares of the medical device company’s stock after selling 4,030 shares during the period. Gladstone Institutional Advisory LLC’s holdings in DexCom were worth $282,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Stableford Capital II LLC grew its stake in shares of DexCom by 2.1% in the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after buying an additional 88 shares in the last quarter. D Orazio & Associates Inc. lifted its position in shares of DexCom by 0.8% during the fourth quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock worth $1,534,000 after purchasing an additional 93 shares in the last quarter. Valley National Advisers Inc. boosted its stake in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. FORVIS Wealth Advisors LLC boosted its stake in shares of DexCom by 0.7% in the fourth quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock valued at $2,033,000 after purchasing an additional 110 shares during the period. Finally, Cary Street Partners Investment Advisory LLC grew its holdings in DexCom by 11.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock valued at $108,000 after purchasing an additional 115 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $125.60 on Friday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The firm has a market cap of $49.95 billion, a P/E ratio of 81.03, a PEG ratio of 3.19 and a beta of 1.23. The stock has a fifty day moving average price of $133.02 and a two-hundred day moving average price of $124.00. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The firm had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. Research analysts forecast that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total value of $1,967,627.99. Following the completion of the sale, the chief operating officer now directly owns 273,913 shares of the company’s stock, valued at $36,816,646.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other DexCom news, CFO Jereme M. Sylvain sold 11,661 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total transaction of $1,567,355.01. Following the transaction, the chief financial officer now owns 85,534 shares in the company, valued at $11,496,624.94. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Jacob Steven Leach sold 14,639 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the completion of the transaction, the chief operating officer now directly owns 273,913 shares in the company, valued at approximately $36,816,646.33. The disclosure for this sale can be found here. In the last 90 days, insiders sold 186,641 shares of company stock worth $25,217,707. 0.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts recently commented on DXCM shares. Canaccord Genuity Group boosted their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. UBS Group lifted their price target on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Royal Bank of Canada began coverage on shares of DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective on the stock. Citigroup boosted their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a research report on Friday, May 17th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average target price of $141.67.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.